News
GSK Gains $370 Million Upfront, Reduced Royalties in CureVac mRNA Patent Settlement Agreement with Pfizer, BioNTech
The settlement ends US mRNA patent disputes involving COVID-19 and influenza vaccines, while positioning GSK for additional payments and global royalty benefits if BioNTech’s acquisition of CureVac closes.
FRANKFURT (Reuters) -German biotech firm BioNTech on Monday said that second-quarter revenues more than doubled to 261 ...
BioNTech also laid off 63 employees in June in conjunction with the discontinuation of its cell therapy manufacturing ...
As part of a "strategic alignment" of its pipeline, BioNTech is laying off 90 workers in R&D and corporate roles across two sites in Maryland and Massachusetts, a spokesperson told Fierce. | As part ...
It's been a good week for BioNTech SE (NASDAQ:BNTX) shareholders, because the company has just released its latest quarterly results, and the shares gained 3.6% to US$111. It was a moderately negative ...
The intervention under investigation is GEN1056, a biological treatment administered via intravenous infusion. Its primary purpose is to evaluate safety and antitumor activity, with the ultimate goal ...
Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.
Stocktwits on MSN4d
BioNTech Gets Price Target Bumps From BofA, Clear Street After Strong Q2, Oncology Pipeline Push
BioNTech is back in Wall Street’s spotlight after posting better-than-expected second-quarter results and doubling down on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback